Katherine Schultheis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Katherine Schultheis has a total of 203 co-authors. Here are the top co-authors by number of shared publications:
Laurent Humeau
8 shared publications- Ziyang Xu
Perelman School of Medicine University of Pennsylvania Philadelphia PA USA
8 shared publications - Daniel W. Kulp
Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA 19104, USA; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
7 shared publications - David B. Weiner
Vaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA, USA
7 shared publications Kate E. Broderick
7 shared publications- Kate E. Broderick
Inovio Pharmaceuticals, Plymouth Meeting, PA 19462, USA
7 shared publications
Latest Publications
- 8 April 2026
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 14  (16) , 4925-4938
Polymersome-based targeted delivery of TLR7/8 agonists enhances cancer immunotherapy
Toll-like receptor 7/8 (TLR7/8) agonists have shown promise as immune stimulants in cancer immunotherapy but have had limited clinical success, largely hampered by safety concerns associated with systemic administration. To overcome this, the design of new molecules featuring lipophilic substituents and encapsulation into nanocarriers for localized delivery offer a rational strategy to enhance therapeutic efficacy while potentially reducing off-target effects. Herein, we report the polymersome-based delivery of a next-generation TLR7/8 agonist (S)-1-(1-(4-butoxyphenyl)-3-ethoxypropan-2-yl)-1H-imidazo[4,5-c]quinolin-4-amine hydrochloride (3M-060), a novel compound with superior immunostimulatory potency encapsulated in nanoscale size polymersomes (ACM-3M-060). ACM-3M-060 elicited stronger induction of pro-inflammatory cytokines than resiquimod (R848) loaded polymersomes (ACM-R848) in human peripheral blood mononuclear cells (PBMCs), while preserving the native activity of the free drug. In a murine CT26 tumor model, intratumoral administration of an ACM-3M-060 analogue labeled with rhodamine led to prolonged retention in the tumor, enhanced drug uptake in the tumor-draining lymph nodes (DLNs) and reduced systemic exposure. Notably, ACM-3M-060 achieved superior tumor growth inhibition compared to the free drug, with a proportion of mice achieving complete tumor regression. Rechallenge with CT26 cells in these animals failed to establish tumors, demonstrating durable antitumor immune memory. This therapeutic effect is primarily driven by TLR7/8-mediated immunomodulation and increased expression of markers of T-cell activity. These findings demonstrate that polymersome delivery enables the safe and effective local administration of potent TLR7/8 agonists such as 3M-060 for cancer immunotherapy.
- 8 April 2026
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 14  (16) , 4925-4938
Polymersome-based targeted delivery of TLR7/8 agonists enhances cancer immunotherapy
Toll-like receptor 7/8 (TLR7/8) agonists have shown promise as immune stimulants in cancer immunotherapy but have had limited clinical success, largely hampered by safety concerns associated with systemic administration. To overcome this, the design of new molecules featuring lipophilic substituents and encapsulation into nanocarriers for localized delivery offer a rational strategy to enhance therapeutic efficacy while potentially reducing off-target effects. Herein, we report the polymersome-based delivery of a next-generation TLR7/8 agonist (S)-1-(1-(4-butoxyphenyl)-3-ethoxypropan-2-yl)-1H-imidazo[4,5-c]quinolin-4-amine hydrochloride (3M-060), a novel compound with superior immunostimulatory potency encapsulated in nanoscale size polymersomes (ACM-3M-060). ACM-3M-060 elicited stronger induction of pro-inflammatory cytokines than resiquimod (R848) loaded polymersomes (ACM-R848) in human peripheral blood mononuclear cells (PBMCs), while preserving the native activity of the free drug. In a murine CT26 tumor model, intratumoral administration of an ACM-3M-060 analogue labeled with rhodamine led to prolonged retention in the tumor, enhanced drug uptake in the tumor-draining lymph nodes (DLNs) and reduced systemic exposure. Notably, ACM-3M-060 achieved superior tumor growth inhibition compared to the free drug, with a proportion of mice achieving complete tumor regression. Rechallenge with CT26 cells in these animals failed to establish tumors, demonstrating durable antitumor immune memory. This therapeutic effect is primarily driven by TLR7/8-mediated immunomodulation and increased expression of markers of T-cell activity. These findings demonstrate that polymersome delivery enables the safe and effective local administration of potent TLR7/8 agonists such as 3M-060 for cancer immunotherapy.
- 31 March 2025
- Published by American Chemical Society (ACS) in Biomacromolecules
- Vol. 26  (4) , 2444-2457
Development of Thermostable and Immunogenic Block Copolymer Nanoparticles (BNPs) for mRNA Delivery
Combining an amphiphilic block copolymer polybutadiene-b-poly(ethylene glycol) (PBD-b-PEO), an ionizable lipid, a helper lipid, and cholesterol produces thermostable BNPs. Luciferase mRNA-BNPs can be stored for over 1 year at 4 °C with no evidence of degradation to the mRNA or nanocarrier. In vivo, mRNA-BNPs exhibit a greater affinity for secondary lymphoid organs than mRNA-lipid nanoparticles (LNPs) and are efficiently taken up by macrophages and dendritic cells. Freshly fabricated ovalbumin (OVA) mRNA-BNPs elicit robust OVA-specific IgG and functional memory CD8+ T cells that persist for at least 5 months. Immunogenicity remains intact after 24 weeks of storage at 4 °C. Anti-PEG antibodies are not boosted by the repeated administration of mRNA-BNPs, unlike mRNA-LNPs. Syrian hamsters vaccinated with SARS-CoV-2 spike mRNA-BNPs are protected against weight loss associated with infection and potently suppress pulmonary viral loads. Protective efficacy is comparable to that conferred by a Comirnaty biosimilar. Cumulatively, mRNA-BNPs are thermostable, immunogenic and possess the potential for clinical application.
- 31 March 2025
- Published by American Chemical Society (ACS) in Biomacromolecules
- Vol. 26  (4) , 2444-2457
Development of Thermostable and Immunogenic Block Copolymer Nanoparticles (BNPs) for mRNA Delivery
Combining an amphiphilic block copolymer polybutadiene-b-poly(ethylene glycol) (PBD-b-PEO), an ionizable lipid, a helper lipid, and cholesterol produces thermostable BNPs. Luciferase mRNA-BNPs can be stored for over 1 year at 4 °C with no evidence of degradation to the mRNA or nanocarrier. In vivo, mRNA-BNPs exhibit a greater affinity for secondary lymphoid organs than mRNA-lipid nanoparticles (LNPs) and are efficiently taken up by macrophages and dendritic cells. Freshly fabricated ovalbumin (OVA) mRNA-BNPs elicit robust OVA-specific IgG and functional memory CD8+ T cells that persist for at least 5 months. Immunogenicity remains intact after 24 weeks of storage at 4 °C. Anti-PEG antibodies are not boosted by the repeated administration of mRNA-BNPs, unlike mRNA-LNPs. Syrian hamsters vaccinated with SARS-CoV-2 spike mRNA-BNPs are protected against weight loss associated with infection and potently suppress pulmonary viral loads. Protective efficacy is comparable to that conferred by a Comirnaty biosimilar. Cumulatively, mRNA-BNPs are thermostable, immunogenic and possess the potential for clinical application.
- 19 January 2024
- Published by American Chemical Society (ACS) in Biomacromolecules
- Vol. 25  (2) , 541-563
Amphiphilic Block Copolymer Nanostructures as a Tunable Delivery Platform: Perspective and Framework for the Future Drug Product Development
Nanoformulation of active payloads or pharmaceutical ingredients (APIs) has always been an area of interest to achieve targeted, sustained, and efficacious delivery. Various delivery platforms have been explored, but loading and delivery of APIs have been challenging because of the chemical and structural properties of these molecules. Polymersomes made from amphiphilic block copolymers (ABCPs) have shown enormous promise as a tunable API delivery platform and confer multifold advantages over lipid-based systems. For example, a COVID booster vaccine comprising polymersomes encapsulating spike protein (ACM-001) has recently completed a Phase I clinical trial and provides a case for developing safe drug products based on ABCP delivery platforms. However, several limitations need to be resolved before they can reach their full potential. In this Perspective, we would like to highlight such aspects requiring further development for translating an ABCP-based delivery platform from a proof of concept to a viable commercial product.
- 19 January 2024
- Published by American Chemical Society (ACS) in Biomacromolecules
- Vol. 25  (2) , 541-563
Amphiphilic Block Copolymer Nanostructures as a Tunable Delivery Platform: Perspective and Framework for the Future Drug Product Development
Nanoformulation of active payloads or pharmaceutical ingredients (APIs) has always been an area of interest to achieve targeted, sustained, and efficacious delivery. Various delivery platforms have been explored, but loading and delivery of APIs have been challenging because of the chemical and structural properties of these molecules. Polymersomes made from amphiphilic block copolymers (ABCPs) have shown enormous promise as a tunable API delivery platform and confer multifold advantages over lipid-based systems. For example, a COVID booster vaccine comprising polymersomes encapsulating spike protein (ACM-001) has recently completed a Phase I clinical trial and provides a case for developing safe drug products based on ABCP delivery platforms. However, several limitations need to be resolved before they can reach their full potential. In this Perspective, we would like to highlight such aspects requiring further development for translating an ABCP-based delivery platform from a proof of concept to a viable commercial product.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Data from A DNA-Launched Nanoparticle Vaccine Elicits CD8+ T-cell Immunity to Promote In Vivo Tumor Control
Cytolytic T cells (CTL) play a pivotal role in surveillance against tumors. Induction of CTL responses by vaccination may be challenging, as it requires direct transduction of target cells or special adjuvants to promote cross-presentation. Here, we observed induction of robust CTL responses through electroporation-facilitated, DNA-launched nanoparticle vaccination (DLnano-vaccines). Electroporation was observed to mediate transient tissue apoptosis and macrophage infiltration, which were deemed essential to the induction of CTLs by DLnano-vaccines through a systemic macrophage depletion study. Bolus delivery of protein nano-vaccines followed by electroporation, however, failed to induce CTLs, suggesting direct in vivo production of nano-vaccines may be required. Following these observations, new DLnano-vaccines scaffolding immunodominant melanoma Gp100 and Trp2 epitopes were designed and shown to induce more potent and consistent epitope-specific CTL responses than the corresponding DNA monomeric vaccines or CpG-adjuvanted peptide vaccines. DNA, but not recombinant protein, nano-vaccinations induced CTL responses to these epitopes and suppressed melanoma tumor growth in mouse models in a CD8+ T-cell–dependent fashion. Further studies to explore the use of DLnano-vaccines against other cancer targets and the biology with which they induce CTLs are important.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from A DNA-Launched Nanoparticle Vaccine Elicits CD8+ T-cell Immunity to Promote In Vivo Tumor Control
Cytolytic T cells (CTL) play a pivotal role in surveillance against tumors. Induction of CTL responses by vaccination may be challenging, as it requires direct transduction of target cells or special adjuvants to promote cross-presentation. Here, we observed induction of robust CTL responses through electroporation-facilitated, DNA-launched nanoparticle vaccination (DLnano-vaccines). Electroporation was observed to mediate transient tissue apoptosis and macrophage infiltration, which were deemed essential to the induction of CTLs by DLnano-vaccines through a systemic macrophage depletion study. Bolus delivery of protein nano-vaccines followed by electroporation, however, failed to induce CTLs, suggesting direct in vivo production of nano-vaccines may be required. Following these observations, new DLnano-vaccines scaffolding immunodominant melanoma Gp100 and Trp2 epitopes were designed and shown to induce more potent and consistent epitope-specific CTL responses than the corresponding DNA monomeric vaccines or CpG-adjuvanted peptide vaccines. DNA, but not recombinant protein, nano-vaccinations induced CTL responses to these epitopes and suppressed melanoma tumor growth in mouse models in a CD8+ T-cell–dependent fashion. Further studies to explore the use of DLnano-vaccines against other cancer targets and the biology with which they induce CTLs are important.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Data from A DNA-Launched Nanoparticle Vaccine Elicits CD8+ T-cell Immunity to Promote In Vivo Tumor Control
Cytolytic T cells (CTL) play a pivotal role in surveillance against tumors. Induction of CTL responses by vaccination may be challenging, as it requires direct transduction of target cells or special adjuvants to promote cross-presentation. Here, we observed induction of robust CTL responses through electroporation-facilitated, DNA-launched nanoparticle vaccination (DLnano-vaccines). Electroporation was observed to mediate transient tissue apoptosis and macrophage infiltration, which were deemed essential to the induction of CTLs by DLnano-vaccines through a systemic macrophage depletion study. Bolus delivery of protein nano-vaccines followed by electroporation, however, failed to induce CTLs, suggesting direct in vivo production of nano-vaccines may be required. Following these observations, new DLnano-vaccines scaffolding immunodominant melanoma Gp100 and Trp2 epitopes were designed and shown to induce more potent and consistent epitope-specific CTL responses than the corresponding DNA monomeric vaccines or CpG-adjuvanted peptide vaccines. DNA, but not recombinant protein, nano-vaccinations induced CTL responses to these epitopes and suppressed melanoma tumor growth in mouse models in a CD8+ T-cell–dependent fashion. Further studies to explore the use of DLnano-vaccines against other cancer targets and the biology with which they induce CTLs are important.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from A DNA-Launched Nanoparticle Vaccine Elicits CD8+ T-cell Immunity to Promote In Vivo Tumor Control
Cytolytic T cells (CTL) play a pivotal role in surveillance against tumors. Induction of CTL responses by vaccination may be challenging, as it requires direct transduction of target cells or special adjuvants to promote cross-presentation. Here, we observed induction of robust CTL responses through electroporation-facilitated, DNA-launched nanoparticle vaccination (DLnano-vaccines). Electroporation was observed to mediate transient tissue apoptosis and macrophage infiltration, which were deemed essential to the induction of CTLs by DLnano-vaccines through a systemic macrophage depletion study. Bolus delivery of protein nano-vaccines followed by electroporation, however, failed to induce CTLs, suggesting direct in vivo production of nano-vaccines may be required. Following these observations, new DLnano-vaccines scaffolding immunodominant melanoma Gp100 and Trp2 epitopes were designed and shown to induce more potent and consistent epitope-specific CTL responses than the corresponding DNA monomeric vaccines or CpG-adjuvanted peptide vaccines. DNA, but not recombinant protein, nano-vaccinations induced CTL responses to these epitopes and suppressed melanoma tumor growth in mouse models in a CD8+ T-cell–dependent fashion. Further studies to explore the use of DLnano-vaccines against other cancer targets and the biology with which they induce CTLs are important.
- Open Access
- 4 February 2022
- Published by Springer Nature in Nature Communications
- Vol. 13  (1) , 1-18
Induction of tier-2 neutralizing antibodies in mice with a DNA-encoded HIV envelope native like trimer
HIV Envelope (Env) is the main vaccine target for induction of neutralizing antibodies. Stabilizing Env into native-like trimer (NLT) conformations is required for recombinant protein immunogens to induce autologous neutralizing antibodies(nAbs) against difficult to neutralize HIV strains (tier-2) in rabbits and non-human primates. Immunizations of mice with NLTs have generally failed to induce tier-2 nAbs. Here, we show that DNA-encoded NLTs fold properly in vivo and induce autologous tier-2 nAbs in mice. DNA-encoded NLTs also uniquely induce both CD4 + and CD8 + T-cell responses as compared to corresponding protein immunizations. Murine neutralizing antibodies are identified with an advanced sequencing technology. The structure of an Env-Ab (C05) complex, as determined by cryo-EM, identifies a previously undescribed neutralizing Env C3/V5 epitope. Beyond potential functional immunity gains, DNA vaccines permit in vivo folding of structured antigens and provide significant cost and speed advantages for enabling rapid evaluation of new HIV vaccines.
- 4 February 2022
- Published by Springer Nature in Nature Communications
- Vol. 13  (1) , 1-18
Open AccessInduction of tier-2 neutralizing antibodies in mice with a DNA-encoded HIV envelope native like trimer
HIV Envelope (Env) is the main vaccine target for induction of neutralizing antibodies. Stabilizing Env into native-like trimer (NLT) conformations is required for recombinant protein immunogens to induce autologous neutralizing antibodies(nAbs) against difficult to neutralize HIV strains (tier-2) in rabbits and non-human primates. Immunizations of mice with NLTs have generally failed to induce tier-2 nAbs. Here, we show that DNA-encoded NLTs fold properly in vivo and induce autologous tier-2 nAbs in mice. DNA-encoded NLTs also uniquely induce both CD4 + and CD8 + T-cell responses as compared to corresponding protein immunizations. Murine neutralizing antibodies are identified with an advanced sequencing technology. The structure of an Env-Ab (C05) complex, as determined by cryo-EM, identifies a previously undescribed neutralizing Env C3/V5 epitope. Beyond potential functional immunity gains, DNA vaccines permit in vivo folding of structured antigens and provide significant cost and speed advantages for enabling rapid evaluation of new HIV vaccines.
- Open Access
- 14 October 2021
- Published by Springer Nature in npj Vaccines
- Vol. 6  (1) , 1-4
INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants
Global surveillance has identified emerging SARS-CoV-2 variants of concern (VOC) associated with broadened host specificity, pathogenicity, and immune evasion to vaccine-induced immunity. Here we compared humoral and cellular responses against SARS-CoV-2 VOC in subjects immunized with the DNA vaccine, INO-4800. INO-4800 vaccination induced neutralizing antibodies against all variants tested, with reduced levels detected against B.1.351. IFNγ T cell responses were fully maintained against all variants tested.
- 14 October 2021
- Published by Springer Nature in npj Vaccines
- Vol. 6  (1) , 1-4
Open AccessINO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants
Global surveillance has identified emerging SARS-CoV-2 variants of concern (VOC) associated with broadened host specificity, pathogenicity, and immune evasion to vaccine-induced immunity. Here we compared humoral and cellular responses against SARS-CoV-2 VOC in subjects immunized with the DNA vaccine, INO-4800. INO-4800 vaccination induced neutralizing antibodies against all variants tested, with reduced levels detected against B.1.351. IFNγ T cell responses were fully maintained against all variants tested.
- Open Access
- 28 September 2021
- Published by Elsevier in Cell Reports Medicine
- Vol. 2  (10) , 100420
Intradermal-delivered DNA vaccine induces durable immunity mediating a reduction in viral load in a rhesus macaque SARS-CoV-2 challenge model
- 28 September 2021
- Published by Elsevier in Cell Reports Medicine
- Vol. 2  (10) , 100420
Open AccessIntradermal-delivered DNA vaccine induces durable immunity mediating a reduction in viral load in a rhesus macaque SARS-CoV-2 challenge model